// App-Quantinova.ai

P209 : Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study

Researchers

Presenter

  • E.V. Loftus

Principal Investigators

  • J.-F. Colombel

  • B. Feagan

  • S. Vermeire

  • W. Sandborn

  • B. Sands

  • S. Danese

  • G. D'Haens

  • A. Kaser

  • R. Panaccione

  • D. Rubin

  • I. Shafran

  • S. O'Byrne

  • P. Geransar

  • A. James

  • A. Kaviya

  • J.M. Khalid

Medical Centers

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Robarts Research Institute, University of Western Ontario, Clinical Trials, London, ON, Canada

  • University hospitals Leuven, Department of clinical and experimental medicine, Leuven, Belgium

  • Univeristy of California San Diego, Division of Gastroenterolgy, San Diego, United States

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy

  • Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands

  • University of Cambridge, Div of Gastroenterology & Hepatology, Dept of Medicine, Cambridge, United Kingdom

  • University of Calgary, Medicine, Calgary, Canada

  • University of Chicago Medical Center, Section of Gastroenterology, Hepatology and Nutrition, Chicago, United States

  • Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom

  • Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

Locations

  • United States

  • Canada

  • Belgium

  • Italy

  • Netherlands

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • NCT00790933

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved